Concepts (304)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vitamin D | 15 | 2020 | 139 | 4.070 |
Why?
|
| Vitamin D Deficiency | 8 | 2019 | 42 | 1.810 |
Why?
|
| Anorectal Malformations | 4 | 2025 | 4 | 1.480 |
Why?
|
| Metabolic Syndrome | 4 | 2022 | 146 | 1.450 |
Why?
|
| Receptors, Calcitriol | 5 | 2022 | 33 | 1.240 |
Why?
|
| Vitamins | 6 | 2019 | 80 | 1.020 |
Why?
|
| Isothiocyanates | 3 | 2020 | 18 | 0.960 |
Why?
|
| Iron | 7 | 2012 | 150 | 0.950 |
Why?
|
| Dietary Supplements | 8 | 2019 | 234 | 0.910 |
Why?
|
| Rectum | 2 | 2025 | 96 | 0.890 |
Why?
|
| Anal Canal | 1 | 2025 | 38 | 0.870 |
Why?
|
| Sulfoxides | 3 | 2020 | 15 | 0.860 |
Why?
|
| Histone Deacetylases | 3 | 2020 | 66 | 0.820 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 1211 | 0.710 |
Why?
|
| Diet, Carbohydrate-Restricted | 3 | 2014 | 10 | 0.660 |
Why?
|
| Enterocytes | 3 | 2008 | 25 | 0.660 |
Why?
|
| Nutritional Status | 5 | 2019 | 98 | 0.630 |
Why?
|
| Calcitriol | 4 | 2008 | 25 | 0.590 |
Why?
|
| Colonic Neoplasms | 1 | 2020 | 219 | 0.570 |
Why?
|
| Caco-2 Cells | 5 | 2020 | 67 | 0.520 |
Why?
|
| RNA, Messenger | 4 | 2008 | 1572 | 0.450 |
Why?
|
| Humans | 43 | 2025 | 64729 | 0.410 |
Why?
|
| Pregnancy Outcome | 3 | 2013 | 197 | 0.400 |
Why?
|
| TRPV Cation Channels | 2 | 2020 | 21 | 0.400 |
Why?
|
| Bronchiolitis, Viral | 1 | 2012 | 4 | 0.380 |
Why?
|
| Intestinal Absorption | 3 | 2018 | 32 | 0.370 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2012 | 39 | 0.360 |
Why?
|
| Iron, Dietary | 4 | 2007 | 9 | 0.360 |
Why?
|
| Ferritins | 6 | 2012 | 30 | 0.350 |
Why?
|
| Diet, Reducing | 1 | 2011 | 27 | 0.350 |
Why?
|
| Obesity | 5 | 2018 | 1263 | 0.340 |
Why?
|
| Diabetes, Gestational | 1 | 2013 | 142 | 0.330 |
Why?
|
| Vascular Diseases | 1 | 2011 | 81 | 0.330 |
Why?
|
| Bone Density Conservation Agents | 2 | 2009 | 45 | 0.320 |
Why?
|
| Diet | 3 | 2007 | 534 | 0.310 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2009 | 5 | 0.310 |
Why?
|
| Fetal Development | 1 | 2009 | 15 | 0.300 |
Why?
|
| Manganese | 1 | 2009 | 20 | 0.300 |
Why?
|
| Trace Elements | 1 | 2009 | 21 | 0.300 |
Why?
|
| Glycemic Index | 1 | 2009 | 23 | 0.300 |
Why?
|
| Birth Weight | 1 | 2009 | 83 | 0.290 |
Why?
|
| Gene Expression | 2 | 2019 | 856 | 0.290 |
Why?
|
| Infant, Newborn | 4 | 2022 | 1410 | 0.260 |
Why?
|
| Female | 21 | 2022 | 33739 | 0.260 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2008 | 63 | 0.260 |
Why?
|
| Adipogenesis | 1 | 2008 | 81 | 0.250 |
Why?
|
| Vitamin D3 24-Hydroxylase | 3 | 2020 | 7 | 0.250 |
Why?
|
| Hyperlipidemias | 1 | 2006 | 34 | 0.250 |
Why?
|
| Diet, High-Fat | 2 | 2018 | 180 | 0.250 |
Why?
|
| Lipoproteins | 1 | 2006 | 85 | 0.240 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2005 | 23 | 0.240 |
Why?
|
| Child | 6 | 2025 | 4599 | 0.230 |
Why?
|
| Weight Loss | 2 | 2014 | 274 | 0.230 |
Why?
|
| Insulin Resistance | 1 | 2009 | 412 | 0.230 |
Why?
|
| Constipation | 1 | 2024 | 15 | 0.220 |
Why?
|
| Lipid Metabolism | 1 | 2006 | 224 | 0.220 |
Why?
|
| Pregnancy | 4 | 2022 | 2363 | 0.220 |
Why?
|
| Heart Diseases | 2 | 2004 | 222 | 0.220 |
Why?
|
| Hirschsprung Disease | 1 | 2024 | 7 | 0.220 |
Why?
|
| Calcium Channels | 2 | 2020 | 104 | 0.220 |
Why?
|
| Gastroenterology | 2 | 2024 | 42 | 0.210 |
Why?
|
| Bladder Exstrophy | 1 | 2023 | 2 | 0.210 |
Why?
|
| Vitamin K 1 | 1 | 2003 | 2 | 0.200 |
Why?
|
| Rectal Prolapse | 1 | 2023 | 11 | 0.200 |
Why?
|
| Urethral Diseases | 1 | 2023 | 13 | 0.200 |
Why?
|
| Deficiency Diseases | 1 | 2003 | 13 | 0.200 |
Why?
|
| Minerals | 1 | 2003 | 20 | 0.200 |
Why?
|
| Micronutrients | 1 | 2003 | 20 | 0.200 |
Why?
|
| Urinary Fistula | 1 | 2023 | 17 | 0.200 |
Why?
|
| Rectal Fistula | 1 | 2023 | 21 | 0.190 |
Why?
|
| Risk Factors | 8 | 2023 | 5393 | 0.190 |
Why?
|
| Calcium, Dietary | 1 | 2002 | 28 | 0.190 |
Why?
|
| Biological Availability | 5 | 2018 | 208 | 0.190 |
Why?
|
| Hypertension | 1 | 2008 | 609 | 0.190 |
Why?
|
| Hemochromatosis | 1 | 2002 | 7 | 0.190 |
Why?
|
| Iron-Sulfur Proteins | 1 | 2002 | 1 | 0.190 |
Why?
|
| Iron-Binding Proteins | 1 | 2002 | 11 | 0.180 |
Why?
|
| Arabs | 1 | 2022 | 8 | 0.180 |
Why?
|
| Cation Transport Proteins | 1 | 2002 | 22 | 0.180 |
Why?
|
| Fecal Incontinence | 1 | 2021 | 32 | 0.170 |
Why?
|
| Urinary Incontinence | 1 | 2021 | 44 | 0.170 |
Why?
|
| Polymorphism, Genetic | 1 | 2022 | 198 | 0.170 |
Why?
|
| Dietary Carbohydrates | 2 | 2014 | 62 | 0.170 |
Why?
|
| Colorectal Neoplasms | 3 | 2011 | 286 | 0.160 |
Why?
|
| Hydroxamic Acids | 1 | 2020 | 28 | 0.160 |
Why?
|
| Postoperative Complications | 2 | 2025 | 1309 | 0.160 |
Why?
|
| Aging | 2 | 2003 | 761 | 0.160 |
Why?
|
| Acetylation | 1 | 2020 | 120 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2014 | 727 | 0.160 |
Why?
|
| Gastrointestinal Diseases | 1 | 2021 | 71 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 582 | 0.160 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 15 | 0.150 |
Why?
|
| Antineoplastic Agents | 2 | 2018 | 640 | 0.140 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 66 | 0.140 |
Why?
|
| Membrane Proteins | 2 | 2017 | 922 | 0.140 |
Why?
|
| Beverages | 2 | 2013 | 68 | 0.140 |
Why?
|
| RNA-Binding Proteins | 1 | 2002 | 447 | 0.140 |
Why?
|
| Odds Ratio | 2 | 2019 | 755 | 0.140 |
Why?
|
| Parathyroid Hormone | 2 | 2012 | 44 | 0.140 |
Why?
|
| Male | 18 | 2023 | 30790 | 0.140 |
Why?
|
| Caloric Restriction | 1 | 2017 | 20 | 0.130 |
Why?
|
| Peptides | 2 | 2017 | 588 | 0.130 |
Why?
|
| Paneth Cells | 1 | 2017 | 6 | 0.130 |
Why?
|
| Mammary Glands, Human | 1 | 2017 | 56 | 0.130 |
Why?
|
| Animals | 10 | 2018 | 21292 | 0.130 |
Why?
|
| Prospective Studies | 3 | 2022 | 3299 | 0.120 |
Why?
|
| Cross-Over Studies | 3 | 2013 | 164 | 0.120 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 148 | 0.120 |
Why?
|
| Treatment Outcome | 2 | 2025 | 5758 | 0.110 |
Why?
|
| United States | 3 | 2021 | 8041 | 0.110 |
Why?
|
| alpha-Tocopherol | 2 | 2012 | 18 | 0.110 |
Why?
|
| Incidence | 2 | 2023 | 1409 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 2680 | 0.110 |
Why?
|
| Receptors, Transferrin | 2 | 2004 | 33 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 605 | 0.110 |
Why?
|
| Drug Delivery Systems | 1 | 2018 | 333 | 0.110 |
Why?
|
| C-Reactive Protein | 2 | 2006 | 168 | 0.110 |
Why?
|
| beta Carotene | 2 | 2012 | 66 | 0.100 |
Why?
|
| Blood Glucose | 2 | 2014 | 494 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 543 | 0.100 |
Why?
|
| Adenoma | 2 | 2011 | 68 | 0.100 |
Why?
|
| Inflammation | 2 | 2017 | 1185 | 0.100 |
Why?
|
| Malus | 1 | 2013 | 3 | 0.100 |
Why?
|
| Catechin | 1 | 2013 | 37 | 0.100 |
Why?
|
| Flavonoids | 1 | 2013 | 57 | 0.100 |
Why?
|
| Cytokines | 1 | 2017 | 951 | 0.100 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2012 | 18 | 0.090 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2017 | 261 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2011 | 702 | 0.090 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2012 | 6 | 0.090 |
Why?
|
| Aged | 9 | 2017 | 14834 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2012 | 81 | 0.090 |
Why?
|
| Respiratory Tract Infections | 1 | 2012 | 86 | 0.090 |
Why?
|
| Vascular Stiffness | 1 | 2011 | 17 | 0.090 |
Why?
|
| Plant Extracts | 1 | 2013 | 129 | 0.090 |
Why?
|
| Infant, Low Birth Weight | 2 | 2009 | 61 | 0.090 |
Why?
|
| Steroid Hydroxylases | 2 | 2008 | 9 | 0.090 |
Why?
|
| Prenatal Care | 1 | 2013 | 169 | 0.080 |
Why?
|
| Evidence-Based Medicine | 2 | 2014 | 456 | 0.080 |
Why?
|
| Societies, Medical | 2 | 2024 | 400 | 0.080 |
Why?
|
| Exercise | 1 | 2017 | 959 | 0.080 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 165 | 0.080 |
Why?
|
| Prevalence | 2 | 2011 | 1432 | 0.080 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 1 | 2009 | 7 | 0.080 |
Why?
|
| Comorbidity | 1 | 2013 | 1115 | 0.080 |
Why?
|
| Oxidative Stress | 2 | 2017 | 317 | 0.070 |
Why?
|
| Pneumonia, Viral | 1 | 2012 | 220 | 0.070 |
Why?
|
| Sunlight | 1 | 2009 | 28 | 0.070 |
Why?
|
| Area Under Curve | 2 | 2013 | 149 | 0.070 |
Why?
|
| Homeostasis | 1 | 2011 | 378 | 0.070 |
Why?
|
| Retrospective Studies | 4 | 2023 | 6803 | 0.070 |
Why?
|
| Gene Expression Regulation | 2 | 2008 | 1633 | 0.070 |
Why?
|
| Bone Density | 1 | 2009 | 142 | 0.070 |
Why?
|
| Epidemiologic Studies | 1 | 2008 | 34 | 0.070 |
Why?
|
| Energy Intake | 1 | 2009 | 173 | 0.070 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2008 | 10 | 0.070 |
Why?
|
| Middle Aged | 9 | 2017 | 18106 | 0.070 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2008 | 14 | 0.070 |
Why?
|
| Benzoquinones | 1 | 2008 | 14 | 0.070 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 1 | 2008 | 22 | 0.070 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 61 | 0.070 |
Why?
|
| Meat | 2 | 2011 | 38 | 0.070 |
Why?
|
| Lactams, Macrocyclic | 1 | 2008 | 31 | 0.070 |
Why?
|
| 3T3-L1 Cells | 1 | 2008 | 90 | 0.070 |
Why?
|
| beta Catenin | 2 | 2018 | 99 | 0.070 |
Why?
|
| Food, Fortified | 2 | 2009 | 19 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2008 | 77 | 0.070 |
Why?
|
| Tretinoin | 1 | 2007 | 49 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2023 | 2049 | 0.060 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 71 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 491 | 0.060 |
Why?
|
| Cholesterol, LDL | 1 | 2006 | 104 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 512 | 0.060 |
Why?
|
| Dactinomycin | 1 | 2005 | 11 | 0.060 |
Why?
|
| Cycloheximide | 1 | 2005 | 22 | 0.060 |
Why?
|
| Interleukin-6 | 2 | 2017 | 325 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 364 | 0.060 |
Why?
|
| Mass Screening | 1 | 2011 | 695 | 0.060 |
Why?
|
| Cholesterol | 1 | 2006 | 261 | 0.060 |
Why?
|
| Mice | 4 | 2018 | 11085 | 0.060 |
Why?
|
| Triglycerides | 1 | 2006 | 248 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2007 | 5562 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2006 | 159 | 0.060 |
Why?
|
| Hydroxyl Radical | 1 | 2004 | 8 | 0.050 |
Why?
|
| Preconception Care | 1 | 2004 | 23 | 0.050 |
Why?
|
| Superoxides | 1 | 2004 | 73 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2024 | 59 | 0.050 |
Why?
|
| Postoperative Care | 1 | 2024 | 122 | 0.050 |
Why?
|
| 1-Carboxyglutamic Acid | 1 | 2003 | 1 | 0.050 |
Why?
|
| Prothrombin | 1 | 2003 | 4 | 0.050 |
Why?
|
| Anticarcinogenic Agents | 2 | 2018 | 33 | 0.050 |
Why?
|
| Colostomy | 1 | 2023 | 25 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2004 | 136 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2004 | 323 | 0.050 |
Why?
|
| Tablets | 1 | 2003 | 16 | 0.050 |
Why?
|
| Protein Binding | 1 | 2008 | 1640 | 0.050 |
Why?
|
| Colectomy | 1 | 2024 | 122 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2004 | 246 | 0.050 |
Why?
|
| Anemia | 1 | 2004 | 130 | 0.050 |
Why?
|
| Permeability | 1 | 2003 | 50 | 0.050 |
Why?
|
| Calcium Carbonate | 1 | 2002 | 4 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 298 | 0.050 |
Why?
|
| DNA | 1 | 2008 | 846 | 0.050 |
Why?
|
| Collagen Type I | 1 | 2002 | 44 | 0.050 |
Why?
|
| Edible Grain | 1 | 2002 | 27 | 0.050 |
Why?
|
| Fasting | 1 | 2002 | 51 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2006 | 885 | 0.050 |
Why?
|
| Vitamin D-Binding Protein | 1 | 2002 | 4 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2004 | 274 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2002 | 53 | 0.050 |
Why?
|
| Hemochromatosis Protein | 1 | 2002 | 6 | 0.050 |
Why?
|
| Milk | 1 | 2002 | 47 | 0.050 |
Why?
|
| Iron-Regulatory Proteins | 1 | 2002 | 2 | 0.050 |
Why?
|
| Colon | 1 | 2023 | 147 | 0.050 |
Why?
|
| Biomarkers | 2 | 2007 | 1465 | 0.050 |
Why?
|
| Citrus | 1 | 2002 | 46 | 0.050 |
Why?
|
| Food | 1 | 2002 | 76 | 0.050 |
Why?
|
| Fruit | 1 | 2002 | 101 | 0.050 |
Why?
|
| Reference Values | 1 | 2002 | 328 | 0.050 |
Why?
|
| Collagen | 1 | 2002 | 134 | 0.050 |
Why?
|
| Pediatrics | 1 | 2024 | 265 | 0.050 |
Why?
|
| HLA Antigens | 1 | 2002 | 62 | 0.050 |
Why?
|
| Protein Biosynthesis | 1 | 2004 | 331 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2021 | 48 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 969 | 0.040 |
Why?
|
| Adult | 5 | 2021 | 17230 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2002 | 145 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2002 | 324 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2013 | 740 | 0.040 |
Why?
|
| Massachusetts | 2 | 2007 | 2137 | 0.040 |
Why?
|
| North America | 1 | 2021 | 113 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2004 | 792 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2018 | 3460 | 0.040 |
Why?
|
| Alcohol Drinking | 1 | 2002 | 322 | 0.040 |
Why?
|
| Transferrin | 2 | 2012 | 70 | 0.040 |
Why?
|
| Calcium | 1 | 2002 | 583 | 0.040 |
Why?
|
| Enteritis | 1 | 2018 | 13 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2002 | 1274 | 0.040 |
Why?
|
| Liver | 1 | 2003 | 867 | 0.040 |
Why?
|
| Infant | 1 | 2023 | 1683 | 0.040 |
Why?
|
| Proteins | 1 | 2004 | 763 | 0.040 |
Why?
|
| Mice, Mutant Strains | 1 | 2018 | 302 | 0.030 |
Why?
|
| F2-Isoprostanes | 1 | 2017 | 5 | 0.030 |
Why?
|
| Albuminuria | 1 | 2017 | 29 | 0.030 |
Why?
|
| Axin Protein | 1 | 2017 | 10 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2017 | 17 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2008 | 3147 | 0.030 |
Why?
|
| Antibodies, Blocking | 1 | 2017 | 39 | 0.030 |
Why?
|
| Creatinine | 1 | 2017 | 135 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2017 | 120 | 0.030 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2017 | 11 | 0.030 |
Why?
|
| Adiposity | 1 | 2017 | 83 | 0.030 |
Why?
|
| Muramidase | 1 | 2017 | 47 | 0.030 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 213 | 0.030 |
Why?
|
| Curriculum | 1 | 2021 | 603 | 0.030 |
Why?
|
| Case-Control Studies | 2 | 2012 | 1135 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2017 | 85 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2002 | 2603 | 0.030 |
Why?
|
| Autophagy | 1 | 2018 | 232 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2017 | 156 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2017 | 173 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 375 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2021 | 723 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2017 | 610 | 0.030 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 273 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2017 | 897 | 0.030 |
Why?
|
| Emulsions | 1 | 2018 | 493 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2017 | 1001 | 0.030 |
Why?
|
| Mutation | 1 | 2002 | 2658 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2014 | 104 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2017 | 1029 | 0.020 |
Why?
|
| Finland | 1 | 2012 | 19 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2017 | 2188 | 0.020 |
Why?
|
| Placebos | 1 | 2012 | 73 | 0.020 |
Why?
|
| Disease Management | 1 | 2014 | 233 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2013 | 164 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2012 | 71 | 0.020 |
Why?
|
| Sigmoidoscopy | 1 | 2011 | 16 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 295 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2011 | 67 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2014 | 797 | 0.020 |
Why?
|
| Young Adult | 2 | 2012 | 4771 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 851 | 0.020 |
Why?
|
| Adolescent | 2 | 2012 | 6291 | 0.020 |
Why?
|
| Adolescent Nutritional Physiological Phenomena | 1 | 2009 | 6 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 670 | 0.020 |
Why?
|
| Brazil | 1 | 2009 | 102 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 506 | 0.020 |
Why?
|
| Retinoid X Receptors | 1 | 2007 | 10 | 0.020 |
Why?
|
| Mice, Inbred A | 1 | 2007 | 20 | 0.020 |
Why?
|
| Nitrosamines | 1 | 2007 | 9 | 0.020 |
Why?
|
| Carcinogens | 1 | 2007 | 33 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2006 | 6 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2012 | 2483 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2007 | 204 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 461 | 0.010 |
Why?
|
| Feeding Behavior | 1 | 2006 | 263 | 0.010 |
Why?
|
| China | 1 | 2004 | 175 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 929 | 0.010 |
Why?
|
| Logistic Models | 1 | 2006 | 1268 | 0.010 |
Why?
|
| Cebidae | 1 | 2002 | 1 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 2270 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 2086 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2006 | 2753 | 0.010 |
Why?
|